PMID- 37476014
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230722
IS  - 2233-4718 (Electronic)
IS  - 2093-940X (Print)
IS  - 2233-4718 (Linking)
VI  - 28
IP  - 2
DP  - 2021 Apr 1
TI  - Total Haemolytic Complement Activity at Diagnosis as an Indicator of the Baseline 
      Activity of Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
PG  - 85-93
LID - 10.4078/jrd.2021.28.2.85 [doi]
AB  - OBJECTIVE: The total haemolytic complement activity (CH50) assay evaluates the 
      functioning of the complement system Accumulating evidence indicates that the 
      activation of the complement system plays a critical role in the pathogenesis of 
      antineutrophil cytoplasmic antibody-associated vasculitis (AAV) Therefore, this 
      study aimed to investigate whether CH50 levels at diagnosis could reflect the 
      baseline activity of AAV. METHODS: This retrospective study included 101 
      immunosuppressive drug-naive patients with AAV At diagnosis, all patients 
      underwent clinical assessments for disease activity, including measurement of the 
      Birmingham Vasculitis Activity Score (BVAS) and Five Factor Score (FFS), and 
      laboratory evaluations, such as tests for CH50, C3, and C4 levels The association 
      between CH50 levels and disease activity was determined. RESULTS: The median BVAS 
      and FFS at diagnosis were 120 and 10, respectively, whereas the median CH50 level 
      was 604 U/mL There was a negative correlation between the CH50 level and BVAS 
      (r=-0241; p=0015) A CH50 cut-off value of 621 U/mL was used to classify the 
      patients into two groups: patients with CH50 levels <621 U/mL (low-CH50 group) 
      and those with CH50 levels >/=621 U/mL (high-CH50 group) The low-CH50 group had a 
      higher proportion of patients with high disease activity, based on the BVAS, than 
      the high-CH50 group (525% vs 238%, p=0004) Additionally, the low-CH50 group 
      exhibited a lower relapse-free survival rate than the high-CH50 group; however, 
      this difference was not statistically significant (p=0082). CONCLUSION: Low CH50 
      levels at diagnosis may reflect high baseline activity of AAV.
CI  - Copyright (c) 2021 by The Korean College of Rheumatology. All rights reserved.
FAU - Pyo, Jung Yoon
AU  - Pyo JY
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
FAU - Lee, Lucy Eunju
AU  - Lee LE
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
FAU - Ahn, Sung Soo
AU  - Ahn SS
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
FAU - Song, Jason Jungsik
AU  - Song JJ
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Korea.
FAU - Park, Yong-Beom
AU  - Park YB
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Korea.
FAU - Lee, Sang-Won
AU  - Lee SW
AUID- ORCID: 0000-0002-8038-3341
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - J Rheum Dis
JT  - Journal of rheumatic diseases
JID - 101571816
PMC - PMC10324888
OTO - NOTNLM
OT  - Activity
OT  - Antineutrophil cytoplasmic antibody
OT  - Complement hemolytic activity assay
OT  - Vasculitis
COIS- CONFLICT OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2021/04/01 00:00
MHDA- 2021/04/01 00:01
PMCR- 2021/04/01
CRDT- 2023/07/21 03:59
PHST- 2020/12/15 00:00 [received]
PHST- 2021/01/11 00:00 [revised]
PHST- 2021/01/14 00:00 [accepted]
PHST- 2021/04/01 00:01 [medline]
PHST- 2021/04/01 00:00 [pubmed]
PHST- 2023/07/21 03:59 [entrez]
PHST- 2021/04/01 00:00 [pmc-release]
AID - jrd-28-2-85 [pii]
AID - 10.4078/jrd.2021.28.2.85 [doi]
PST - ppublish
SO  - J Rheum Dis. 2021 Apr 1;28(2):85-93. doi: 10.4078/jrd.2021.28.2.85.